TrialClinical cancer research : an official journal of the American Association for Cancer Research2019

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).

Ingrid A Mayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.